IL293191B2 - Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use - Google Patents
Heterocyclic compounds as delta-5 desaturase inhibitors and methods of useInfo
- Publication number
- IL293191B2 IL293191B2 IL293191A IL29319122A IL293191B2 IL 293191 B2 IL293191 B2 IL 293191B2 IL 293191 A IL293191 A IL 293191A IL 29319122 A IL29319122 A IL 29319122A IL 293191 B2 IL293191 B2 IL 293191B2
- Authority
- IL
- Israel
- Prior art keywords
- trifluoromethyl
- methyl
- pyrimidin
- pyrazol
- imidazo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962939821P | 2019-11-25 | 2019-11-25 | |
| PCT/US2020/062020 WO2021108408A1 (en) | 2019-11-25 | 2020-11-24 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL293191A IL293191A (en) | 2022-07-01 |
| IL293191B1 IL293191B1 (en) | 2025-05-01 |
| IL293191B2 true IL293191B2 (en) | 2025-09-01 |
Family
ID=73855555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL293191A IL293191B2 (en) | 2019-11-25 | 2020-11-24 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11512097B2 (enExample) |
| EP (1) | EP4065223A1 (enExample) |
| JP (2) | JP7254246B2 (enExample) |
| KR (2) | KR102598203B1 (enExample) |
| CN (2) | CN118161500A (enExample) |
| AR (1) | AR120556A1 (enExample) |
| AU (1) | AU2020392087B2 (enExample) |
| BR (1) | BR112022010054A2 (enExample) |
| CA (1) | CA3162281A1 (enExample) |
| CL (2) | CL2022001357A1 (enExample) |
| CO (1) | CO2022008690A2 (enExample) |
| CR (1) | CR20220308A (enExample) |
| IL (1) | IL293191B2 (enExample) |
| JO (1) | JOP20220125A1 (enExample) |
| MX (1) | MX2022006281A (enExample) |
| PE (1) | PE20231097A1 (enExample) |
| PH (1) | PH12022551282A1 (enExample) |
| SA (1) | SA522432710B1 (enExample) |
| TW (2) | TWI815061B (enExample) |
| UY (1) | UY38971A (enExample) |
| WO (1) | WO2021108408A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11220510B2 (en) * | 2018-04-09 | 2022-01-11 | Incyte Corporation | Pyrrole tricyclic compounds as A2A / A2B inhibitors |
| CN118161500A (zh) | 2019-11-25 | 2024-06-11 | 安进公司 | 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法 |
| CN115557903A (zh) * | 2022-09-27 | 2023-01-03 | 山东潍坊润丰化工股份有限公司 | 一种特草定的制备方法 |
| WO2024112763A1 (en) | 2022-11-23 | 2024-05-30 | Amgen Inc. | Selection of patients for the treatment of fads1-mediated diseases or disorders using fads-1 inhibitors |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3130633A1 (de) | 1981-08-01 | 1983-02-17 | Basf Ag, 6700 Ludwigshafen | 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide |
| EP0242690B1 (en) | 1986-04-07 | 1993-06-30 | Kumiai Chemical Industry Co., Ltd. | 5H-1,3,4-Thiadiazolo[3,2-a]pyrimidin-5-one derivatives and agricultural-horticultural fungicide composition containing the same |
| US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| JP2002514196A (ja) | 1996-12-05 | 2002-05-14 | アムジエン・インコーポレーテツド | 置換ピリミジノンおよびピリドン化合物ならびに使用方法 |
| WO2001029044A1 (en) | 1999-10-15 | 2001-04-26 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| US6537998B1 (en) * | 1999-10-15 | 2003-03-25 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| WO2003106435A1 (en) | 2002-06-18 | 2003-12-24 | Sankyo Company, Limited | Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof |
| JP2004107228A (ja) | 2002-09-17 | 2004-04-08 | Nippon Nohyaku Co Ltd | 双環性ピリミジノン誘導体及びこれを有効成分とする除草剤 |
| US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| AR049769A1 (es) | 2004-01-22 | 2006-09-06 | Novartis Ag | Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina |
| JP5118975B2 (ja) | 2004-12-24 | 2013-01-16 | アストラゼネカ・アクチエボラーグ | Ｃｃｒ２ｂアンタゴニストとしてのヘテロ環式化合物 |
| JP2008546843A (ja) | 2005-06-27 | 2008-12-25 | アムゲン インコーポレイティッド | 抗炎症性アリールニトリル化合物 |
| WO2007027012A1 (en) | 2005-07-18 | 2007-03-08 | Samsung Electronics Co., Ltd. | Video coding method and apparatus for reducing mismatch between encoder and decoder |
| EP1910373A1 (de) | 2005-07-27 | 2008-04-16 | Basf Se | Fungizide 6-phenyl-triazolopyrimidinylamine |
| EP1909580A1 (de) | 2005-07-27 | 2008-04-16 | Basf Se | Fungizide 5-methyl-6-phenyl-triazolopyrimidinylamine |
| WO2007012601A1 (de) | 2005-07-27 | 2007-02-01 | Basf Aktiengesellschaft | Fungizide 6-phenyl-pyrazolopyrimidin-7-ylamine |
| US20070082900A1 (en) | 2005-10-06 | 2007-04-12 | Schering Corporation | Methods for inhibiting protein kinases |
| WO2008037459A1 (en) | 2006-09-28 | 2008-04-03 | Novartis Ag | Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use |
| CA2665476A1 (en) | 2006-10-05 | 2008-04-10 | Cv Therapeutics, Inc. | Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors |
| WO2008057601A2 (en) | 2006-11-08 | 2008-05-15 | The Rockefeller University | Organic compounds |
| US20080194557A1 (en) | 2007-01-18 | 2008-08-14 | Joseph Barbosa | Methods and compositions for the treatment of pain, inflammation and cancer |
| WO2008089310A2 (en) | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of obesity |
| EP2066177B1 (de) | 2007-01-19 | 2014-12-24 | Basf Se | Fungizide mischungen aus 1-methylpyrazol-4-ylcarbonsäureaniliden und azolopyrimidinylaminen |
| EP2131658A2 (en) | 2007-01-30 | 2009-12-16 | Basf Se | Method for improving plant health |
| US8461077B2 (en) | 2007-03-23 | 2013-06-11 | Basf Se | Combinations of active substances |
| JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| WO2009124259A1 (en) | 2008-04-04 | 2009-10-08 | Cv Therapeutics, Inc. | Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors |
| US8119647B2 (en) | 2008-04-23 | 2012-02-21 | Glenmark Pharmaceuticals S.A. | Fused pyrimidineone compounds as TRPV3 modulators |
| US20100099561A1 (en) | 2008-10-15 | 2010-04-22 | E.I. Du Pont De Nemours And Company | Heterobicyclic alkylthio-bridged isoxazolines |
| WO2010087467A1 (en) | 2009-01-27 | 2010-08-05 | Takeda Pharmaceutical Company Limited | Delta-5-desaturase inhibitors |
| CN102482278B (zh) | 2009-06-29 | 2015-04-22 | 因塞特公司 | 作为pi3k抑制剂的嘧啶酮类 |
| WO2011114148A1 (en) | 2010-03-17 | 2011-09-22 | Astrazeneca Ab | 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists |
| WO2012011592A1 (ja) | 2010-07-23 | 2012-01-26 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| WO2013177538A2 (en) | 2012-05-24 | 2013-11-28 | Colorado State University Research Foundation | Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease |
| US10035801B2 (en) | 2013-03-13 | 2018-07-31 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
| CA2922925A1 (en) | 2013-09-05 | 2015-03-12 | Genentech, Inc. | Antiproliferative compounds |
| WO2015064714A1 (ja) | 2013-10-31 | 2015-05-07 | 国立大学法人東京大学 | オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体 |
| WO2015135094A1 (en) | 2014-03-13 | 2015-09-17 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| EP3683222B1 (en) | 2014-04-23 | 2021-10-06 | Mitsubishi Tanabe Pharma Corporation | Novel bicyclic or tricyclic heterocyclic compound |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| JP6791717B2 (ja) | 2015-10-22 | 2020-11-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
| JP2017091808A (ja) | 2015-11-10 | 2017-05-25 | 株式会社フジクラ | 酸化物超電導線材の製造方法及び超電導コイルの製造方法 |
| US11414385B2 (en) | 2015-12-21 | 2022-08-16 | The University Of Chicago | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases |
| MA46092A (fr) | 2016-08-31 | 2021-04-21 | Agios Pharmaceuticals Inc | Inhibiteurs de processus métaboliques cellulaires |
| WO2018039972A1 (en) * | 2016-08-31 | 2018-03-08 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
| CN106749271B (zh) * | 2016-12-07 | 2019-04-05 | 青岛科技大学 | 一类[1,2,4]-三氮唑并[1,5-a]嘧啶酮类杂环化合物、其制备方法及其用途 |
| WO2018213365A1 (en) | 2017-05-15 | 2018-11-22 | Dana-Farber Cancer Institute, Inc. | Compounds for treating dengue virus infection and other viral infections |
| WO2018229683A1 (en) | 2017-06-15 | 2018-12-20 | Novartis Ag | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases |
| MA50256A (fr) | 2017-09-15 | 2020-07-22 | Aduro Biotech Inc | Composés de pyrazolopyrimidinone et leurs utilisations |
| CN118161500A (zh) | 2019-11-25 | 2024-06-11 | 安进公司 | 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法 |
-
2020
- 2020-11-24 CN CN202410291075.3A patent/CN118161500A/zh active Pending
- 2020-11-24 CR CR20220308A patent/CR20220308A/es unknown
- 2020-11-24 AU AU2020392087A patent/AU2020392087B2/en active Active
- 2020-11-24 KR KR1020227021152A patent/KR102598203B1/ko active Active
- 2020-11-24 IL IL293191A patent/IL293191B2/en unknown
- 2020-11-24 CN CN202080081465.8A patent/CN114728167B/zh active Active
- 2020-11-24 JP JP2022529556A patent/JP7254246B2/ja active Active
- 2020-11-24 WO PCT/US2020/062020 patent/WO2021108408A1/en not_active Ceased
- 2020-11-24 EP EP20828193.1A patent/EP4065223A1/en active Pending
- 2020-11-24 BR BR112022010054A patent/BR112022010054A2/pt unknown
- 2020-11-24 KR KR1020237037455A patent/KR20230154292A/ko active Pending
- 2020-11-24 PE PE2022000849A patent/PE20231097A1/es unknown
- 2020-11-24 JO JOP/2022/0125A patent/JOP20220125A1/ar unknown
- 2020-11-24 PH PH1/2022/551282A patent/PH12022551282A1/en unknown
- 2020-11-24 MX MX2022006281A patent/MX2022006281A/es unknown
- 2020-11-24 CA CA3162281A patent/CA3162281A1/en active Pending
- 2020-11-24 US US17/103,389 patent/US11512097B2/en active Active
- 2020-11-25 AR ARP200103274A patent/AR120556A1/es unknown
- 2020-11-25 TW TW109141315A patent/TWI815061B/zh active
- 2020-11-25 UY UY0001038971A patent/UY38971A/es unknown
- 2020-11-25 TW TW112142068A patent/TWI867822B/zh active
-
2021
- 2021-03-16 US US17/203,457 patent/US20210221824A1/en not_active Abandoned
-
2022
- 2022-05-24 CL CL2022001357A patent/CL2022001357A1/es unknown
- 2022-05-24 SA SA522432710A patent/SA522432710B1/ar unknown
- 2022-06-22 CO CONC2022/0008690A patent/CO2022008690A2/es unknown
- 2022-11-18 US US18/056,863 patent/US12448396B2/en active Active
-
2023
- 2023-03-27 JP JP2023049452A patent/JP7698676B2/ja active Active
- 2023-08-22 CL CL2023002486A patent/CL2023002486A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7421507B2 (ja) | ハンチントン病を処置するためのヘテロ環式およびヘテロアリール化合物 | |
| US12448396B2 (en) | Methods of using heterocyclic compounds as Delta-5 Desaturase inhibitors | |
| JP7743484B2 (ja) | 大環状ｋｒａｓ阻害剤及び使用方法 | |
| EP2867236B1 (en) | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors | |
| WO2023091726A1 (en) | Inhibitors of cyclin‑dependent kinase 12 (cdk12) | |
| KR20170083134A (ko) | 시르투인 조정제로서의 치환된 가교된 우레아 유사체 | |
| JP2019534324A (ja) | Ｐｄｅ１阻害剤としてのイミダゾピラジノン、ピラゾロピリミジノンおよびピラゾロピリジノン | |
| US12473289B2 (en) | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | |
| EA048401B1 (ru) | Гетероциклические соединения в качестве ингибиторов дельта-5-десатуразы и способы применения | |
| WO2022166796A1 (zh) | 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途 | |
| HK1204619B (en) | 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |